Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | DGKA | P23743 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | PAM | P19021 | 2/20 | 0.45 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2066617 | 1.00 | MAPT (0.50) | MAPTDGKALMNAKDM4EDUSP3 | |
| SCHEMBL11527155 | 0.88 | MAPT (0.54) | MAPTDGKALMNAKDM4EDUSP3 | |
| SCHEMBL665783 | 0.88 | MAPT (0.54) | MAPTDGKALMNAKDM4EDUSP3 | |
| SCHEMBL9722921 | 0.88 | MAPT (0.54) | MAPTDGKALMNAKDM4EDUSP3 | |
| SCHEMBL9219407 | 0.88 | MAPT (0.54) | MAPTDGKALMNAKDM4EDUSP3 | |
| SCHEMBL30439420 | 0.88 | MAPT (0.54) | MAPTDGKALMNAKDM4EDUSP3 | |
| SCHEMBL19695188 | 0.88 | MAPT (0.54) | MAPTDGKALMNAKDM4EDUSP3 | |
| Alcohol SCHEMBL6359960 | 0.85 | LMNA (0.53) | MAPTDGKALMNAKDM4EDUSP3 | |
| SCHEMBL14246769 | 0.84 | CYP3A4 (0.51) | MAPTDGKALMNAKDM4EDUSP3 | |
| SCHEMBL31065847 | 0.83 | LMNA (0.50) | MAPTDGKALMNAKDM4EDUSP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148321-B2 | Bioconjugates as therapeutic agent and synthesis thereof | NATIONAL INSTITUTE OF IMMUNOLOGY (US) | 2012-04-03 | — | — | US | claimed |
| US-20090088372-A1 | Novel Bioconjugates As Therapeutic Agent and Synthesis Thereof | NATIONAL INSTITUTE OF IMMUNOLOGY (IN) | 2009-04-02 | — | — | US | claimed |
| EP-1996236-A2 | NOVEL BIOCONJUGATES AS THERAPEUTIC AGENT AND SYNTHESIS THEREOF | National Institute of Immunology (IN) | 2008-12-03 | — | — | EP | claimed |
| WO-2007108013-A2 | NOVEL BIOCONJUGATES AS THERAPEUTIC AGENT AND SYNTHESIS THEREOF | NATIONAL INSTITUTE OF IMMUNOLOGY (IN) | 2007-09-27 | — | — | WO | claimed |
| US-8148321-B2 | Bioconjugates as therapeutic agent and synthesis thereof | NATIONAL INSTITUTE OF IMMUNOLOGY (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090088372-A1 | Novel Bioconjugates As Therapeutic Agent and Synthesis Thereof | NATIONAL INSTITUTE OF IMMUNOLOGY (IN) | 2009-04-02 | — | — | US | disclosed |
| EP-1996236-A2 | NOVEL BIOCONJUGATES AS THERAPEUTIC AGENT AND SYNTHESIS THEREOF | National Institute of Immunology (IN) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007108013-A2 | NOVEL BIOCONJUGATES AS THERAPEUTIC AGENT AND SYNTHESIS THEREOF | NATIONAL INSTITUTE OF IMMUNOLOGY (IN) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088372-A1 | Novel Bioconjugates As Therapeutic Agent and Synthesis Thereof | DNPEP, LNPEP, RNPEP | MAPT 3602/4885DGKA 2219/4885LMNA 1551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.